Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience.

Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Blood (Impact Factor: 9.78). 06/2001; 97(12):3727-32. DOI: 10.1182/blood.V97.12.3727
Source: PubMed

ABSTRACT To describe the clinical and biologic features of pediatric acute megakaryoblastic leukemia (AMKL) and to identify prognostic factors, experience at St Jude Children's Research Hospital was reviewed. Of 281 patients with acute myeloid leukemia treated over a 14-year period, 41 (14.6%) had a diagnosis of AMKL. Six patients had Down syndrome and AMKL, 6 had secondary AMKL, and 29 had de novo AMKL. The median age of the 22 boys and 19 girls was 23.9 months (range, 6.7-208.9 months). The rate of remission induction was 60.5%, with a 48% rate of subsequent relapse. Patients with Down syndrome had a significantly higher 2-year event-free survival (EFS) estimate (83%) than did other patients with de novo AMKL (14%) or with secondary AMKL (20%; P < or =.038). Among patients who had de novo AMKL without Down syndrome, 2-year EFS was significantly higher after allogeneic bone marrow transplantation (26%) than after chemotherapy alone (0%; P =.019) and significantly higher when performed during remission (46%) than when performed during persistent disease (0%; P =.019). The 5-year survival estimates were significantly lower for de novo AMKL (10%) than for other forms of de novo AML (42%; P <.001). Treatment outcome is very poor for patients with AMKL in the absence of Down syndrome. Remission induction is the most important prognostic factor. Allogeneic transplantation during remission offers the best chance of cure; in the absence of remission, transplantation offers no advantage over chemotherapy alone. (Blood. 2001;97:3727-3732)

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Long non-coding RNAs (lncRNAs) are recognized as pivotal players during developmental ontogenesis and pathogenesis of cancer. The intronic microRNA (miRNA) clusters miR-99a ~ 125b-2 and miR-100 ~ 125b-1 promote progression of acute megakaryoblastic leukemia (AMKL), an aggressive form of hematologic cancers. The function of the lncRNA hostgenes MONC and MIR100HG within this ncRNA ensemble remained elusive.
    Molecular cancer. 07/2014; 13(1):171.
  • Progress in Biotechnology - PROGR BIOTECHNOL. 01/1998; 15:725-730.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Differentiation therapy has emerged as a powerful way to target specific hematologic malignancies. One of the best examples is the use of All-trans-Retinoic acid (ATRA) in Acute Promyelocytic Leukemia (APL), which has significantly improved the outcome for patients with this specific form of Acute Myeloid Leukemia (AML). In considering how differentiation therapy could be used in other forms of AML, we predicted that compounds that induce terminal differentiation of megakaryocytes would be effective therapies for the megakaryocytic form of AML, named Acute Megakaryocytic Leukemia (AMKL). We also speculated that such agents would reduce the burden of abnormal hematopoietic cells in Primary Myelofibrosis (PMF) and alter the differentiation of megakaryocytes in Myelodysplastic Syndromes (MDS). Using a high-throughput chemical screening approach, we identified small molecules that promote many features of terminal megakaryocyte differentiation, including the induction of polyploidization, the process by which cells accumulate DNA to 32N or greater. Since the induction of polyploidization is an irreversible process, cells that enter this form of the cell cycle do not divide again. Thus, this would be an effective way to reduce the tumor burden. Clinical studies with polyploidy inducers, such as Aurora kinase A inhibitors, are underway for a wide variety of malignancies, while trials specifically for AMKL and PMF are in development. This novel form of differentiation therapy may be clinically available in the not too distant future.
    Clinical Cancer Research 08/2013; · 8.19 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014